InvestSMART

Telix Pharmaceuticals Limited (ASX:TLX)

ALERT: Price-sensitive ASX Announcement for TLX
Current share price for TLX : $16.260 -0.58 (-3.44%)+
Announcement
Release
20 Aug 2026 8:41AM
Price at Release
$16.840
Full Release
download
Summary
Telix Pharmaceuticals Limited reported strong financial results for the first half of 2026, with a revenue increase of 22% to US$477 million and a gross margin improvement to 55%. The company achieved a profit after tax of US$38 million, including a significant contribution from a collaboration with Regeneron. Telix's precision medicine segment showed solid performance, driven by the growth of Illuccix® and Gozellix®. Major advancements were made in their therapeutic pipeline, including progress in prostate cancer and glioblastoma treatments. The company also entered a strategic collaboration with Regeneron and completed refinancing of its convertible bonds. Guidance for the full year 2026 anticipates revenues exceeding US$1 billion, supported by continued R&D investments.
Key Points
  • Group revenue increased by 22% to US$477 million.
  • Gross margin improved to 55%, with precision medicine gross margin at 65%.
  • Net profit after tax was US$38 million, with US$40 million from Regeneron collaboration.
  • Adjusted EBITDA rose by 146% year-over-year to US$52 million.
  • Significant progress in late-stage therapeutic programs for prostate cancer and glioblastoma.
  • Entered strategic collaboration with Regeneron.
  • Refinancing of convertible bonds completed, issuing US$600 million of new bonds.
  • Full year 2026 revenue guidance expected to exceed US$1 billion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.